AI summary · may contain errors
A CAR-restricted CRISPRa expansion platform enables genome-wide CRISPRa-CAR T survival screens with ~10 9 cells, sustaining >85% on-target overexpression across cytokine milieus.
- 1 opens in JClub
- Open access
Moving in Cancer Discovery, Molecular Therapy Nucleic Acids and Nature Medicine.
Rebuilt
AI summary · may contain errors
A CAR-restricted CRISPRa expansion platform enables genome-wide CRISPRa-CAR T survival screens with ~10 9 cells, sustaining >85% on-target overexpression across cytokine milieus.
AI summary · may contain errors
China approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy for claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer.
AI summary · may contain errors
Anti-CAR antibodies in brain tumor patients are linked to limited durability of chimeric antigen receptor T-cell therapy, undermining the engineered receptor’s persistence.
AI summary · may contain errors
Amsokigene autoleucel (amsoki-cel, OBX-115) with acetazolamide regulation shows no dose-limiting toxicities across 37 ICI-resistant advanced melanoma patients, with RP2D enabling responses.
Newest first · last 60 days
AI summary · may contain errors
A single intravenous dose of T-IDLE STCE in a murine Sjögren's syndrome-associated dry eye model induces deep, time-limited depletion of plasmablasts and plasma cells.
AI summary · may contain errors
NKG2D overexpression in CAR-T cells (CAR-NG) reduces NK-cell–mediated cytotoxic susceptibility and improves tumor control in hematologic and solid tumor models.
AI summary · may contain errors
Antigen-scaffold expansion of CRISPR-Cas9-engineered TCR T cells and anti-CD19 CAR T cells yields an average 69% (±22%) antigen-specific T cells after 14 days.
AI summary · may contain errors
DVD-3E, a protease-activatable logic-gated T cell engager pro-drug, enables conditional IL-2 and TCR cosignaling in solid tumor models, producing potent antitumor responses without systemic toxicity.
AI summary · may contain errors
eTasR, an engineered ParTasR variant fused to TREX2, boosts PAMless genome editing in mammalian cells from 4.29% to 48.94%, averaging a 26.52-fold increase.
AI summary · may contain errors
CAR-engineered dendritic cells using CLEC9A or DEC205 intracellular domains enhance antigen uptake and cross-presentation, linked to SYK phosphorylation and stronger antitumor T-cell responses in mouse models.
AI summary · may contain errors
PRGN-3008 CD19 CAR T cells engineered with mbIL-15 and PD-1-targeting microRNAs preserve polyfunctionality and sustained cytotoxicity across repeated tumor challenges.
AI summary · may contain errors
B7-H3-targeted CAR-engineered NK cells show antigen-specific cytotoxicity against atypical teratoid/rhabdoid tumors and prolong survival in orthotopic xenograft mouse models.
AI summary · may contain errors
P2RX5-FL is expressed by up to 75% of individuals with African ancestry and is stable on the plasma membrane, enabling CAR T targeting.
AI summary · may contain errors
Adoptive transfer of stem-like CD8+ T cells followed by intravenous vaccination prevents immune exclusion in the tumor microenvironment and reprograms tumor cells to upregulate IFN signaling programs.
AI summary · may contain errors
hAB2 CAR-T cells selectively eradicate CALRmut myeloproliferative neoplasm–sustaining stem cells in patient-derived tumor xenografts, eliminating all detectable MPN-propagating function in serial transplantation assays.
AI summary · may contain errors
Temporally gated MANAGE CAR-T cells using a FITC-sensing synNotch receptor reduce exhaustion and preserve stem-like phenotypes versus constitutive CAR-T in solid-tumor in vivo models.
AI summary · may contain errors
CD16HSC-NKT stem cell–derived invariant natural killer T cells enhanced monoclonal antibody therapy across diverse tumor models, achieving durable eradication and prolonged survival in xenografts.
AI summary · may contain errors
A TCR warehouse library from healthy donors targeting KRAS G12d and G12v neoantigens covers ~one-quarter of pancreatic ductal adenocarcinoma patients and 10% of colorectal cancer patients.
AI summary · may contain errors
A CD19/HIV dual CAR T strategy in a humanized mouse leukemia model eradicated tumors comparable to CD19-only CAR T, while a CD19.BBζ-IL-18 plus CD4.28ζ-C34-CXCR4* design enhanced HIV and tumor control.
AI summary · may contain errors
A single infusion of mivocabtagene autoleucel in antibody-positive adult stiff person syndrome improved timed 25-ft walk at week 16 by a mean of -7.69 seconds (P<.001).
AI summary · may contain errors
Entirely virus-free CAR T cells with synthetic CAR DNA inserted at TRAC or CD3ζ loci show in vitro cytotoxicity comparable to lentiviral universal 41BB-CD3ζ CAR T cells, but xenograft leukemia control is not superior.
AI summary · may contain errors
Donor-derived hexaviral-specific T cells targeting CMV, AdV, EBV, BKV, HPIV3, and HHV6 were tolerated in 14 post-HCT patients, with 8/8 evaluable showing partial or complete responses at 3 months.
AI summary · may contain errors
AVO-100, an AAV6 capsid with CD3scFv inserted into one capsid protein, achieved more than 200-fold higher transduction of primary human T cells and enabled complete eradication of CD19+ Raji xenografts.
AI summary · may contain errors
Local irradiation of human riTNF CAR-T cells drives high tumor necrosis factor (TNF) secretion and yields greater tumor regression than either riTNF CAR-T alone or irradiation alone in xenograft and murine models.
AI summary · may contain errors
HLA restrictions limit the applicability of T-cell receptor therapies across genetically diverse human populations, creating fairness challenges that stakeholders must address.
AI summary · may contain errors
Transient p38 MAPK inhibition during CRISPR-Cas9 editing of human HSPCs reduces micronuclei and lowers long-term mutational burden without increasing detectable structural genome alterations.
AI summary · may contain errors
Cytokine release syndrome identification and grading in immune-cell-engaging therapy trials remains inconsistent, undermining safety decisions and cross-trial comparisons despite ASTCT being the most practical standard.
Journals this month
Topics moving, week to 18 Nov 2026
By field